ML141 is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase. The EC₅₀ for Cdc42 wild type and Cdc42Q61L mutant were 2.1 and 2.6 μM respectively. It has excellent selectivity for Cdc42 with no inhibition toward Rho and Rac in the same GTPase family, including Rac1, Rab2 and Rab7. In cellular assays ML141 inhibited Cdc42-related filopodia formation and cell migration.

How to Use:

• In vitro:  ML141 was used at 10 µM final concentration in various in vitro assays.
• In vivo: not reported

Reference:

• 1. Chen HY, et al. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. (2013) EMBO Mol Med. 5(5):723-36.
• 2. Surviladze Z, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. (2010) Probe Reports from the NIH Molecular Libraries Program.